SCHEMBL614591

SCHEMBL614591

COCOc1ccc(Br)c(OCOC)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.40
ABL1 P00519 1/20 0.40
EGFR P00533 1/20 0.40
HCK P08631 1/20 0.40
SRC P12931 1/20 0.40
KDR P35968 1/20 0.40
PIK3CA P42336 1/20 0.40
PIK3CB P42338 1/20 0.40
MTOR P42345 1/20 0.40
PIK3CG P48736 1/20 0.40
EPHB4 P54760 1/20 0.40
PRKDC P78527 1/20 0.40
MAPT P10636 2/20 0.39
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 1/20 0.37
FYN P06241 3/20 0.37
ROR1 Q01973 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
SLC6A4 P31645 1/20 0.35
HDAC8 Q9BY41 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30639283 0.91 FYN (0.45) MAPTKDM4EALDH1A1FYNROR1
SCHEMBL30926051 0.91 MAPT (0.47) PIK3CDABL1EGFRHCKSRC
SCHEMBL2176515 0.91 FYN (0.45) MAPTKDM4EALDH1A1FYNROR1
SCHEMBL152145 0.91 MAPT (0.47) PIK3CDABL1EGFRHCKSRC
SCHEMBL6952285 0.89 MAPT (0.46) PIK3CDABL1EGFRHCKSRC
SCHEMBL16925411 0.85 MAPT (0.48) MAPTKDM4EALDH1A1FYNROR1
SCHEMBL31253956 0.84 PIK3CD (0.41) PIK3CDABL1EGFRHCKSRC
SCHEMBL29924000 0.84 SLC6A4 (0.40) MAPTKDM4EALDH1A1SMN1; SMN2SLC6A4
SCHEMBL17386359 0.84 MAOB (0.50) MAPTSMN1; SMN2HDAC6CYP2C19HIF1A
SCHEMBL19617265 0.83 SCD (0.33) PIK3CDABL1EGFRHCKSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4698520-A1 RAF-MEK PROTEIN COMPLEX MODULATORS AND METHODS OF USE THEREOF Gandeeva Therapeutics, Inc. (US) 2026-02-25 EP disclosed
WO-2024220708-A1 RAF-MEK PROTEIN COMPLEX MODULATORS AND METHODS OF USE THEREOF GANDEEVA THERAPEUTICS, INC. (US) 2024-10-24 WO disclosed
US-20160207943-A1 Apparatus and Methods for the Automated Synthesis of Small Molecules THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2016-07-21 US disclosed
EP-3018136-A1 APPARATUS AND METHODS FOR THE AUTOMATED SYNTHESIS OF SMALL MOLECULES The Board of Trustees of the University of Illionis (US) 2016-05-11 EP disclosed
EP-2596000-B1 APPARATUS AND METHODS FOR THE AUTOMATED SYNTHESIS OF SMALL MOLECULES UNIV ILLINOIS (US) 2016-04-20 EP disclosed
US-9238597-B2 Apparatus and methods for the automated synthesis of small molecules THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2016-01-19 US disclosed
CN-102238948-B Novel 4-(heterocycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and also in cosmetics GALDERMA RES & DEV 2015-03-25 CN disclosed
EP-2529735-B1 COMPOSITIONS COMPRISING 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL DERIVATIVES WITH TYROSINASE ENZYME INHIBITING ACTIVITY GALDERMA RES & DEV (FR) 2014-06-25 EP disclosed
EP-2529735-B1 COMPOSITIONS COMPRISING 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL DERIVATIVES WITH TYROSINASE ENZYME INHIBITING ACTIVITY GALDERMA RES & DEV (FR) 2014-06-25 EP disclosed
US-20130243670-A1 Apparatus and Methods for the Automated Synthesis of Small Molecules THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2013-09-19 US disclosed
EP-1318974-A2 RESORCINOL DERIVATIVES Pfizer Products Inc. (US) 2003-06-18 EP disclosed
US-6541473-B2 Use as skin lightening agents; 4-(1,4-Dioxaspiro(4.5)dec-8-yl)-1,3-benzenediol for example WARNER LAMBERT COMPANY 2003-04-01 US disclosed
US-20020161041-A1 Resorcinol derivatives PFIZER INC. 2002-10-31 US disclosed
US-20020155075-A1 For use as topical depigmention agents that have good efficacy and are harmless COLLINGTON ERIC WILLIAM (GB) 2002-10-24 US disclosed
US-20020137961-A1 Resorcinol derivatives PFIZER INC. 2002-09-26 US disclosed
WO-2002024613-A2 RESORCINOL DERIVATIVES PFIZER PRODUCTS, INC. (US) 2002-03-28 WO disclosed
EP-1165031-A1 RESORCINOL COMPOSITION PFIZER INC. (US) 2002-01-02 EP disclosed
EP-1165495-A1 RESORCINOL DERIVATIVES PFIZER INC. (US) 2002-01-02 EP disclosed
WO-2000056702-A1 RESORCINOL DERIVATIVES PFIZER INC. (US) 2000-09-28 WO disclosed
WO-2000056279-A1 RESORCINOL COMPOSITION PFIZER INC. (US) 2000-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130243670-A1 Apparatus and Methods for the Automated Synthesis of Small Molecules PCNA, BLK, FAR1 PIK3CD 1493/4885ABL1 239/4885EGFR 500/4885
US-20020155075-A1 For use as topical depigmention agents that have good efficacy and are harmless TYR, QDPR, DBH PIK3CD 4348/4885ABL1 2920/4885EGFR 4591/4885
US-20160207943-A1 Apparatus and Methods for the Automated Synthesis of Small Molecules PCNA, BLK, FAR1 PIK3CD 1493/4885ABL1 239/4885EGFR 500/4885
US-20020161041-A1 Resorcinol derivatives NQO1, LRAT, ALDH1A2 PIK3CD 1663/4885ABL1 4363/4885EGFR 4367/4885
US-20020137961-A1 Resorcinol derivatives LRAT, NQO1, ALDH1A2 PIK3CD 1499/4885ABL1 4354/4885EGFR 4279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.